Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by Eversept Partners LP

Eversept Partners LP trimmed its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 22.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,600,015 shares of the company's stock after selling 450,142 shares during the period. Vera Therapeutics comprises about 6.0% of Eversept Partners LP's investment portfolio, making the stock its 3rd biggest position. Eversept Partners LP owned about 2.53% of Vera Therapeutics worth $67,665,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Huntington National Bank bought a new position in shares of Vera Therapeutics during the 4th quarter worth approximately $26,000. AlphaQuest LLC bought a new stake in shares of Vera Therapeutics in the 4th quarter worth about $34,000. KBC Group NV increased its position in shares of Vera Therapeutics by 127.2% during the 4th quarter. KBC Group NV now owns 2,477 shares of the company's stock worth $105,000 after purchasing an additional 1,387 shares in the last quarter. Summit Investment Advisors Inc. boosted its position in Vera Therapeutics by 16.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock valued at $196,000 after buying an additional 639 shares in the last quarter. Finally, Moors & Cabot Inc. bought a new stake in Vera Therapeutics during the fourth quarter worth about $220,000. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Trading Down 0.8 %

Shares of NASDAQ:VERA opened at $21.11 on Tuesday. The stock has a market capitalization of $1.35 billion, a PE ratio of -8.09 and a beta of 1.28. The company's 50-day moving average price is $25.82 and its two-hundred day moving average price is $36.33. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics, Inc. has a one year low of $18.53 and a one year high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.11. On average, equities analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Wolfe Research initiated coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price target on the stock. Guggenheim raised their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a report on Thursday, February 27th. The Goldman Sachs Group initiated coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They issued a "buy" rating and a $58.00 price objective on the stock. Finally, JPMorgan Chase & Co. dropped their price objective on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a report on Tuesday, March 4th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $64.67.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

Want to see what other hedge funds are holding VERA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.